We demonstrated that plasma EGFR and KRAS mutation testing using PNA-based real-time PCR methods is feasible and can be applied as an alternative to tumor genotyping when deciding upon the optimal treatment of NSCLC patients. Here, KRAS is linked to neoplasm.